Shaanxi Panlong Pharmaceutical Group Limited By Share 002864.SZ · CNY
Health Care · Shenzhen · 🇨🇳 China
22.21
+10.00%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shaanxi Panlong Pharmaceutical Group Limited By Share
Its shares trade on Shenzhen under the ticker 002864.SZ. It has been listed since 16 November 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.14bn and net income of CN¥96.3m. At that date it held total assets of CN¥2.32bn and shareholders' equity of CN¥1.69bn.
Shaanxi Panlong Pharmaceutical Group Ltd. By Share Ltd. engages in the GAP planting of medicinal materials, drug production, research and development, sales and medical logistics. The company is headquartered in Xi'An, Shaanxi. The company went IPO on 2017-11-16. The firm's main product is Panlong Qipian, which is for the treatment of orthopedic rheumatism diseases. The firm also provides other Chinese patent drugs for the treatment of hepatobiliary, cardiovascular and cerebrovascular, gynecological and anti-tumor diseases. The firm is also involved in the production and sales of Chinese herbal pieces, as well as the medical commercial distribution business. The firm distributes its products within domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 16 Nov 2017
- Employees
- 935
- Website
- pljt.com ↗
Leadership
Pay as last reported
- Mr. Xiaolin XieChairman of the Board, since 2013CN¥366,000
- Mr. Dezhu ZhangActing President, Vice President, Director, since 2013CN¥124,800
- Mr. Fengming ZhuChief Financial OfficerCN¥120,300
- Mr. Jilin HuangDeputy General Manager, Director, since 2020CN¥299,500
- Mr. Zhong MengDeputy General ManagerCN¥109,500
- Mr. Jie WuSecretary of the Board, Director, since 2013CN¥153,600
- Mr. Xiaofeng XieDirector
- Mr. Wenfeng ZhuStaff Elected Director, since 2025
- Mr. Xiaofeng NiuIndependent DirectorCN¥33,300
- Mr. Mancang WangIndependent Director
- Mr. Peng WangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shaanxi Panlong Pharmaceutical Group employs 935 full-time employees for drug production and R&D.
- Panlong Qipian is a main product for treating orthopedic rheumatism diseases.
- The company distributes products within the domestic market through medical logistics.
Weaknesses
- The company's main product Panlong Qipian is limited to orthopedic rheumatism treatment.
- The firm's business is confined to domestic market distribution only.
- The company has no international presence or expansion plans mentioned.
Opportunities
- The firm provides Chinese patent drugs for hepatobiliary and cardiovascular diseases.
- Shaanxi Panlong Pharmaceutical Group engages in GAP planting of medicinal materials.
- The company offers medical commercial distribution business for Chinese herbal pieces.
Threats
- The company's products are limited to domestic market without international expansion.
- No mention of R&D investments beyond current product lines.
- The firm's business is solely focused on Chinese patent drugs and herbal pieces.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.